Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans
Giacomo Salvadore, Pascal Bonaventure, Anantha Shekhar, et al.
Translational Psychiatry (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

Hypocretins (orexins): The ultimate translational neuropeptides
Laura H. Jacobson, Daniël Hoyer, Luı́s de Lecea
Journal of Internal Medicine (2022) Vol. 291, Iss. 5, pp. 533-556
Closed Access | Times Cited: 71
The Orexin/Hypocretin System, the Peptidergic Regulator of Vigilance, Orchestrates Adaptation to Stress
Miklós Jászberényi, Balázs Thurzó, Zsolt Bagosi, et al.
Biomedicines (2024) Vol. 12, Iss. 2, pp. 448-448
Open Access | Times Cited: 22
Alleviating anxiety and taming trauma: Novel pharmacotherapeutics for anxiety disorders and posttraumatic stress disorder
Nicolas Singewald, Simone B. Sartori, Andreas Reif, et al.
Neuropharmacology (2023) Vol. 226, pp. 109418-109418
Open Access | Times Cited: 37
Targeting Orexin Receptors for the Treatment of Insomnia: From Physiological Mechanisms to Current Clinical Evidence and Recommendations
Maria P. Mogavero, Alessandro Silvani, Giuseppe Lanza, et al.
Nature and Science of Sleep (2023) Vol. Volume 15, pp. 17-38
Open Access | Times Cited: 23
Identification of a novel perifornical-hypothalamic-area-projecting serotonergic system that inhibits innate panic and conditioned fear responses
Cristian Bernabe, Izabela Facco Caliman, Aline Rezende Abreu, et al.
Translational Psychiatry (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 8
Discovery and first-time disclosure of CVN766, an exquisitely selective orexin 1 receptor antagonist
Angela Glen, Roland W. Bürli, David G. Livermore, et al.
Bioorganic & Medicinal Chemistry Letters (2024) Vol. 100, pp. 129629-129629
Open Access | Times Cited: 8
Hypocretin/Orexin Receptor Pharmacology and Sleep Phases
Yu Sun, Ryan K. Tisdale, Thomas S. Kilduff
Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences (2021), pp. 22-37
Open Access | Times Cited: 42
Pharmacological Treatment of Generalised Anxiety Disorder: Current Practice and Future Directions
Harry Fagan, David S. Baldwin
Expert Review of Neurotherapeutics (2023) Vol. 23, Iss. 6, pp. 535-548
Open Access | Times Cited: 21
Targeting the orexin/hypocretin system for the treatment of neuropsychiatric and neurodegenerative diseases: From animal to clinical studies
Marc Ten-Blanco, África Flores, Luigia Cristino, et al.
Frontiers in Neuroendocrinology (2023) Vol. 69, pp. 101066-101066
Open Access | Times Cited: 19
Targeting orexin receptors: Recent advances in the development of subtype selective or dual ligands for the treatment of neuropsychiatric disorders
Alessandro Bonifazi, Fabio Del Bello, Gianfabio Giorgioni, et al.
Medicinal Research Reviews (2023) Vol. 43, Iss. 5, pp. 1607-1667
Closed Access | Times Cited: 13
Biosynthesis and structure assignment of a hydroxylated metabolite of the orexin-1 receptor antagonist JNJ-61393215
Fengbin Song, Jie Chen, Shannon Dallas, et al.
Bioorganic & Medicinal Chemistry (2025) Vol. 121, pp. 118130-118130
Closed Access
Orexin receptors: possible therapeutic targets for psychiatric disorders
Shigeyuki Chaki
Psychopharmacology (2025)
Closed Access
Reviewing the role of the orexinergic system and stressors in modulating mood and reward-related behaviors
Salar Vaseghi, Shahram Zarrabian, Abbas Haghparast
Neuroscience & Biobehavioral Reviews (2021) Vol. 133, pp. 104516-104516
Closed Access | Times Cited: 23
Amygdalar CB2 cannabinoid receptor mediates fear extinction deficits promoted by orexin-A/hypocretin-1
Marc Ten-Blanco, África Flores, Inmaculada Pereda-Pérez, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 149, pp. 112925-112925
Open Access | Times Cited: 18
Evaluating the efficacy of the selective orexin 1 receptor antagonist nivasorexant in an animal model of binge‐eating disorder
Michel A. Steiner, Luca Botticelli, Giorgio Bergamini, et al.
International Journal of Eating Disorders (2024) Vol. 57, Iss. 7, pp. 1418-1432
Open Access | Times Cited: 2
Estradiol-dependent hypocretinergic/orexinergic behaviors throughout the estrous cycle
Hye Ji J. Kim, Samuel A. Dickie, Robert B. Laprairie
Psychopharmacology (2022) Vol. 240, Iss. 1, pp. 15-25
Open Access | Times Cited: 9
Use of experimental medicine approaches for the development of novel psychiatric treatments based on orexin receptor modulation
Amy C. Beckenstrom, Preciosa Coloma, Gerard R. Dawson, et al.
Neuroscience & Biobehavioral Reviews (2023) Vol. 147, pp. 105107-105107
Open Access | Times Cited: 5
Blockade of orexin receptor 1 attenuates morphine protracted abstinence-induced anxiety-like behaviors in male mice
Hongming Ye, Tong Cao, Qigang Shu, et al.
Psychoneuroendocrinology (2023) Vol. 151, pp. 106080-106080
Open Access | Times Cited: 5
Brain Mechanisms Underlying Panic Attack and Panic Disorder
Xuyan Guan, Peng Cao
Neuroscience Bulletin (2023) Vol. 40, Iss. 6, pp. 795-814
Closed Access | Times Cited: 5
Orexin Receptor Antagonists for the Prevention and Treatment of Alzheimer’s Disease and Associated Sleep Disorders
Matteo Carpi, Nicola Biagio Mercuri, Claudio Liguori
Drugs (2024)
Open Access | Times Cited: 1
Dual Cannabinoid and Orexin Regulation of Anhedonic Behaviour Caused by Prolonged Restraint Stress
Hye Ji J. Kim, Ayat Zagzoog, Costanza Ceni, et al.
Brain Sciences (2023) Vol. 13, Iss. 2, pp. 314-314
Open Access | Times Cited: 4
Anxiety Disorders
David S. Baldwin, Bethan Impey, Vasilios G. Masdrakis
Cambridge University Press eBooks (2024), pp. 293-313
Closed Access | Times Cited: 1
International Union of Basic and Clinical Pharmacology CXIV: Orexin Receptor Function, Nomenclature and Pharmacology
Jyrki P. Kukkonen, Laura H. Jacobson, Daniël Hoyer, et al.
Pharmacological Reviews (2024), pp. PHARMREV-000953
Open Access | Times Cited: 1
Experimental Drugs for Panic Disorder: An Updated Systematic Review
Daniela Caldirola, Alessandra Alciati, Francesco Cuniberti, et al.
Journal of Experimental Pharmacology (2021) Vol. Volume 13, pp. 441-459
Open Access | Times Cited: 10
CO2 reactivity as a biomarker of exposure-based therapy non-response: study protocol
Jasper A. J. Smits, Marie‐H. Monfils, Michael W. Otto, et al.
BMC Psychiatry (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top